S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q2 2021

Baker Bros Advisors

Period: Q2 2021 Β· Filed: 2021-08-16
View on SEC EDGAR β†—
AUM
$22.77B
Total portfolio value
Positions
120
Reported securities
Top Holding
SGEN
32.8% $7.47B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2021-08-16) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$7.47B32.79%β€”β€”
32.8%
ONCBeiGene, Ltd.$4.00B17.59%$343.19$297.65-13.3%
17.6%
INCYIncyte Corporation$2.69B11.83%$84.13$116.86+38.9%
11.8%
KODKodiak Sciences Inc.$1.31B5.77%$93.00$38.54-58.6%
5.8%
ACADACADIA Pharmaceuticals Inc.$1.02B4.49%$24.39$25.97+6.5%
4.5%
BMRNBioMarin Pharmaceutical Inc.$633.3M2.78%$83.44$58.99-29.3%
2.8%
ASNDAscendis Pharma A/S$465.7M2.05%$131.55$274.50+108.7%
2.0%
NVTAQInvitae Corporation$345.7M1.52%β€”β€”
1.5%
ARGXargenx SE$337.1M1.48%$301.07$939.68+212.1%
1.5%
PRLDPrelude Therapeutics Incorporated$289.9M1.27%$28.63$4.91-82.8%
1.3%
IGMSIGM Biosciences, Inc.$262.6M1.15%β€”β€”
1.1%
ABCLAbCellera Biologics Inc.$229.9M1.01%$22.00$8.11-63.1%
1.0%
MRTXMirati Therapeutics, Inc.$227.7M1.00%β€”β€”
1.0%
BCRXBioCryst Pharmaceuticals, Inc.$201.0M0.88%$15.81$9.84-37.8%
0.9%
MDGLMadrigal Pharmaceuticals, Inc.$146.0M0.64%$97.41$528.10+442.1%
0.6%
APLSApellis Pharmaceuticals, Inc.$143.6M0.63%$63.20β€”
0.6%
HRTXHeron Therapeutics, Inc.$126.2M0.55%$15.52$0.44-97.2%
0.6%
AMRNXXXXAmarin Corporation plc$115.9M0.51%β€”β€”
0.5%
GBTGlobal Blood Therapeutics, Inc.$112.7M0.49%β€”β€”
0.5%
PACBPacific Biosciences of California, Inc.$112.0M0.49%$34.97$1.68-95.2%
0.5%
IMCRImmunocore Holdings plc$98.4M0.43%$39.05$32.50-16.8%
0.4%
KYMRKymera Therapeutics, Inc.$95.0M0.42%$48.50$113.51+134.0%
0.4%
VSTMXXXXVerastem, Inc.$87.5M0.38%β€”β€”
0.4%
VERVVerve Therapeutics, Inc.$85.3M0.37%β€”β€”
0.4%
TLISTalis Biomedical Corporation$83.5M0.37%β€”β€”
0.4%
CERSCerus Corporation$81.0M0.36%$5.91$3.16-46.5%
0.4%
DBVTDBV Technologies S.A.$79.8M0.35%$10.92$15.82+44.9%
0.3%
RYTMRhythm Pharmaceuticals, Inc.$75.6M0.33%$19.58$114.17+483.1%
0.3%
TILInstil Bio, Inc.$75.2M0.33%$386.40$7.73-98.0%
0.3%
LEGNLegend Biotech Corporation$68.3M0.30%$41.05$29.91-27.1%
0.3%

Quarter-on-Quarter Activity

Q2 2021 vs. Q1 2021

New Positions (8)

TickerIssuerNotional
VERVVerve Therapeutics, Inc.$85.3M
Insmed Incorporated$44.1M
AVTEAerovate Therapeutics, Inc.$32.6M
Apellis Pharmaceuticals, Inc.$27.8M
Tricida, Inc.$27.3M
CYTTCyteir Therapeutics, Inc.$17.4M
CNTACentessa Pharmaceuticals plc$8.9M
BMEABiomea Fusion, Inc.$4.6M

Exited Positions (8)

TickerIssuerNotional
ALXNAlexion Pharmaceuticals, Inc.$610.6M
CCXIChemoCentryx, Inc.$33.6M
XNCRXencor, Inc.$15.9M
SGMOSangamo Therapeutics, Inc.$5.4M
SRPTSarepta Therapeutics, Inc.$4.4M
CNSTConstellation Pharmaceuticals, Inc.$2.7M
IDRAIdera Pharmaceuticals, Inc.$2.7M
AUTLAutolus Therapeutics plc$2.6M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
LEGNLegend Biotech Corporation$65.0M+1339.6%-27.1%
Sarepta Therapeutics, Inc.$26.5M+218.0%
CHMAChiasma, Inc.$4.4M+91.4%
ORTXOrchard Therapeutics plc$-0.1M+62.3%
CRNXCrinetics Pharmaceuticals, Inc.$7.9M+49.3%
KDNYChinook Therapeutics, Inc.$3.6M+44.3%
ASMBAssembly Biosciences, Inc.$1.1M+36.8%
APLSApellis Pharmaceuticals, Inc.$71.8M+35.7%

Trimmed (8)

TickerIssuerNotionalShares Ξ”
SYRSSyros Pharmaceuticals, Inc.$-4.8M-90.5%
PTGXProtagonist Therapeutics, Inc.$-16.8M-68.3%
MREOMereo BioPharma Group plc$-14.8M-63.4%
ALTAltimmune, Inc.$-28.4M-61.1%
PASGPassage Bio, Inc.$-2.6M-50.2%
GMDAQGamida Cell Ltd.$-4.5M-41.1%
NVTAQInvitae Corporation$-256.1M-34.9%
AUPHAurinia Pharmaceuticals Inc.$-3.8M-20.6%
← Back to Hedge Funds